Author

J. Sansa-Girona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

G. Pons· 2 shared J. Roma· 2 shared J. Sanchez de Toledo· 2 shared L. Garcia-Gilabert· 2 shared L. Moreno· 2 shared M. F. Segura· 2 shared N. Navarro· 2 shared P. Zarzosa· 2 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Pons

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

G. O. Gallo-Oller, G. Pons, J. Sansa-Girona, N. Navarro, P. Zarzosa, L. Garcia-Gilabert, P. Cabre Fernandez, G. Guillen Barrieza, L. Valero-Arrese, M. F. Segura, J. M. Lizcano, J. Sanchez de Toledo, L. Moreno, S. Gallego, J. Roma

This study shows TRIB3 silencing reduces Akt pathway activity and PAX3-FOXO1 levels in high-risk rhabdomyosarcoma, leading to decreased tumor growth and improved survival.

bioRxiv · Dec 1, 2023Cancer Biology

Analysis of cancer genomic amplifications identifies druggable collateral dependencies within the amplicon

G. Pons, G. Gallo-Oller, N. Navarro, P. Zarzosa, J. Sansa-Girona, L. Garcia-Gilabert, A. Magdaleno, M. F. Segura, J. Sanchez de Toledo, S. Gallego, L. Moreno, J. Roma

The paper identifies druggable collateral dependencies in cancer genomic amplifications using CRISPR/Cas9 screens and integrates gene dependency with druggability and subcellular location data.

bioRxiv · Nov 16, 2022Cancer Biology